Evercrisp Biosciences, Inc.

NEW YORK, NY · Founded 2021 · Biotech · Private

Tissue-targeting technologies for systemic genetic medicine delivery

Claim this profile

Follows are private to you and power your alerts

Updated · evercrispbio.com

Sector
Biotech
Headquarters
NEW YORK, NY
Founded
2021
Latest Form D
$3.5M, Aug 2021
Total capital
$3.5M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$3.5M
1 Form D · last Aug 2021
62 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
6 pending

Capital timeline

2021FEDERAL ↑EQUITY ↓Cumulative $3.5M1st Form D$3.5M
2021FEDERAL ↑EQUITY ↓Cumulative $3.5M1st Form D$3.5M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$3.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Anna BatarinaDirectorNamed in SEC Form D filings
  • Seth HarrisonDirectorNamed in SEC Form D filings
  • Spiros LirasExecutive Officer, DirectorNamed in SEC Form D filings
  • Tanja KortemmeDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 6
  • PendingDelivery Compounds, Compositions, And Methods Of Use ThereofUSPTOApplication PCTUS2025057529
  • PendingModified Crispr-cas Effector Polypeptides And Methods Of Use ThereofUSPTOApplication PCTUS2025011097
  • PendingModified Crispr-cas Effector Polypeptides And Methods Of Use ThereofUSPTOApplication 63727069
Show all 6 patent records
  • Delivery Compounds, Compositions, And Methods Of Use ThereofApplication PCTUS2025057529Pending
  • Modified Crispr-cas Effector Polypeptides And Methods Of Use ThereofApplication PCTUS2025011097Pending
  • Modified Crispr-cas Effector Polypeptides And Methods Of Use ThereofApplication 63727069Pending
  • Delivery Compounds, Compositions, And Methods Of Use ThereofApplication 63727081Pending
  • Modified Crispr-cas Effector Polypeptides And Methods Of Use ThereofApplication 63619705Pending
  • Modified Crispr-cas Effector Polypeptides And Methods Of Use ThereofApplication 19604456Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .